Optimizing patient access with evidence of product value, effectiveness, and safety from early development through loss of exclusivity.

Learn More

The Spring Issue of The Evidence Forum is Out

Read content related to the relevant issues facing companies along the path to approval and access

Read Now

Perspective Paper

Four Considerations to Shape Your Orphan Drug Designation Application Strategy

Discover the importance of approaching an orphan drug designation application with a strong strategy

Read Now

Committed to Supporting Clients During the COVID-19 Pandemic

Access resources and information related to COVID-19 studies to discover how we are joining the COVID-19 fight

Learn More

Evidera's Experts Recognized for Contributions to Mitchell B. Balter Award-Winning Article for 2021

Access the latest issue of the Journal of Clinical Psychopharmacology to learn more

Learn More

White Paper

Implementation Science: A Primer

Gain insight into the definition of implementation science and the key stakeholders, value, and study approaches involved

Read Now

Our Work In Action

150+ Drugs/Therapies

supported in the past year

30+ Global Extended Access Programs

in the last 3 years alone with thousands of patients transitioning smoothly from investigational to commercial

130+ Payer Submissions

across 20+ countries in the past 5 years, including reversal of multiple NICE decisions

17 of the 20 Top-Selling Drugs

in 2018 supported in the past 5 years

130+ Peer-Reviewed Publications

and 220+ research posters and presentations per year

Learn More

Latest Publications

Psychiatry/Psychology

Patient Perspectives and Experiences of Preventive Treatments and Self-Injectable Devices for Migraine: A Focus Group Study

Patient
August 2021

Neurology

Modeling Long-Term Health and Economic Implications of New Treatment Strategies for Parkinson’s Disease: An Individual Patient Simulation Study

Journal of Market Access & Health Policy
July 2021

Any

Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations

Value Health
July 2021

What We Do

Real-World Evidence & Data Solutions

Obtain real-world evidence to optimize product value, effectiveness, safety, and market strategy by extracting data from existing sources, collecting primary data, and conducting hybrid studies.

Non-Interventional Studies

Robust design, epidemiologic and therapeutic area insights, advanced data analytics and precision study execution critical for study and program success.

Interventional Studies

Provide peri- and post-approval evidence via dedicated global operations and custom-tailored study designs.

Patient-Centered Research

Develop and evaluate clinical outcomes assessments to support labeling and promotional claims.

Evidence Synthesis, Modeling & Communication

Provide a truly connected value story, supported by strong evidence

Value & Development Consulting

End-to-end regulatory, clinical development, and value and access consulting services that span all phases of development.

Medical Writing

Expert medical writing, including medical information, study documentation, and publications, tailored to the peri- and post-approval environment.

In Our Own Words

A virtual or decentralized approach puts the focus where it should be—on the patients. Our decentralized approach and study innovations maximize data collection while minimizing burden to patients, caregivers, and healthcare providers to answer important research questions.

Mariah Baltezegar, MBA, Executive Director, Head of PPA Virtual Trials, Real-World Evidence

Oncology – An Exciting Time of New Hope and New Challenges Feature Image

Case Study

Real-World Data Insights from LiveTracker® Determine Prescribing Trends for Cancers with High PD-L1 Protein Expression

Evidera's Real-World Data Solutions team used LiveTracker to evaluate HCP-reported data on treatment patterns in patients with non-small cell lung cancer and melanoma.

Case Study

Oncology Developer Utilizes Integrated Scientific Advice to Optimize Phase III Trial, Aligning Regulator and HTA Needs

Gain insight into how Evidera’s Value & Development Consulting team leveraged our Integrated Scientific Advice (ISA) offering to provide feedback to drug developers to optimize their evidence generation plans and satisfy stakeholder requirements.

Case Study

Six-Year Collaboration Across Six Indications for Groundbreaking Oncology Therapy

Evidera's Evidence Synthesis, Modeling & Communication team generated integrated packages of evidence, including value messaging, systematic reviews and comparative effectiveness analyses, and economic models, for six indications.

Case Study

Virtual Expanded Access Program Providing Breast Cancer Patients Early Access to Treatment During the COVID-19 Pandemic

Evidera was able to provide a virtual approach to mitigate the risk to patient safety during the COVID-19 pandemic and enabled early patient access to 400 US breast cancer patients ahead of commercial availability.

Case Study

Enhancing Oncology Market Access with a Real-World Evidence EAMS Add-on

Discover how Evidera researchers designed an observational study to conceptualize and implement real-world data collection in an Early Access to Medicines Scheme (EAMS) for an oncology therapy.

Case Study

Evidera Led Effort to Qualify the First Biomarker for COPD Trial Enrichment

Learn how Evidera's partnership with the COPD Foundation Biomarker Qualification Consortium led to the qualification of plasma fibrinogen as the first biomarker in COPD for enrichment of clinical trials by the FDA.

Careers

Meaningful Work at Every Level

We assess candidates across a variety of scientific and operational functions. From leaders in their fields, to those who are new to the industry. We employ people who have a proactive mind-set when it comes to the work they do and helping the people they work with.

Learn More